Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts

Oncology Reports

Volumn 24, Issue 6, 2010, Pages 1509-1514

  Na, Young Soon ^a   Kim, Seung Mi ^a   Jung, Kyung Ah ^a   Yang, Soo Jin ^a   Hong, Yong Sang ^a   Ryu, Min Hee ^a   Ro, Seonggu ^a,b   Cho, Dong Hyung ^a   Kim, Jin Cheon ^a   Jin, Dong Hoon ^a   Lee, Jung Shin ^a   Kim, Tae Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b CrystalGenomics Inc   (South Korea)

Author keywords

5 FU; CG2; Colon cancer; Histone deacetylase inhibitors; Irinotecan; Oxaliplatin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACTIN; CASPASE 3; CASPASE 8; CASPASE 9; CG2; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXALIPLATIN; PROTEIN P21; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MORNING DOSAGE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NAPHTHALENES; ORGANOPLATINUM COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649411701     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001012     Document Type: Article

References (21)

1. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
2. Teicher BA: Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75: 1262-1271, 2008.
3. Jennerwein MM, Eastman A and Khokhar A: Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum (II) complexes. Chem Biol Interact 70: 39-49, 1989.
4. Kohne CH and Lenz HJ: Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 14: 478-488, 2009.
5. Glozak MA and Seto E: Histone deacetylases and cancer. Oncogene 26: 5420-5432, 2007.
6. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ and Ladner RD: Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer 125: 463-473, 2009.
7. Frew AJ, Lindemann RK, Martin BP, et al: Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 105: 11317-11322, 2008.
8. Kim JC, Shin ES, Kim CW, et al: In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. Anticancer Res 29: 3027-3034, 2009.
9. Kim JC, Kim DD, Lee YM, et al: Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 24: 209-218, 2009.
10. Na Y-S, Jung K-A, Kim S-M, et al: The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. Cancer Chemother Pharmacol (In press).
11. Tumber A, Collins LS, Petersen KD, et al: The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60: 275-283, 2007.
12. Piacentini P, Donadelli M, Costanzo C, et al: Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 448: 797-804, 2006.
13. Zhang X, Yashiro M, Ren J and Hirakawa K: Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16: 563-568, 2006.
14. Glaser KB: HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74: 659-671, 2007.
15. Munshi A, Tanaka T, Hobbs ML, et al: Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5: 1967-1974, 2006.
16. Takemura H, Rao VA, Sordet O, et al: Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem 281: 30814-30823, 2006.
17. Chinnaiyan P, Chowdhary S, Brem S, et al: A Phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma. Merk, NCT00762255, 2009.
18. Flis S, Gnyszka A and Splawinski J: HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun 387: 336-341, 2009.
19. Todd RC and Lippard SJ: Inhibition of transcription by platinum antitumor compounds. Metallomics 1: 280-291, 2009.
20. Glaser KB, Staver MJ, Waring JF, et al: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163, 2003.
21. Lee JH, Park JH, Jung Y, et al: Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 5: 3085-3095, 2006.